Skip to main content
. Author manuscript; available in PMC: 2019 Jul 28.
Published in final edited form as: J Control Release. 2018 Mar 6;282:13–24. doi: 10.1016/j.jconrel.2018.02.042

Fig. 2.

Fig. 2

Distribution and anti-tumor efficacy of FTn/FTn–PEG particles in mouse lung and proximal lung cancer model. a) in vivo distribution of FTn or FTn/FTn–PEGx (PEG sizes = 2, 5, and 10 kDa) labeled with Cy5 in large airways. Red (particles) DAPI (cell nuclei), b) quantification of labeled nanoparticles. Mice were administered intratracheally with particles and harvested at 10 minutes, and c) quantification of total fluorescence intensity throughout mouse trachea. FTn/FTn–PEG2k/DOX were administered intratracheally in an orthotopic mouse model of proximal lung cancer. d) IVIS imaging of 3LL lung tumor tissue bioluminescence signal over time, e) quantification of bioluminescence signal, and f) survival study of mice treated with and without treatment. Reprinted with permission from reference[45].